1/11/2020 Antimicrobial Resistance Pattern in Enterococcus faecalis Strains Isolated From Expressed Prostatic Secretions of Patients With Ch…

Antimicrobial Resistance Pattern in Enterococcus faecalis Strains Isolated From Expressed

Prostatic Secretions of Patients With Chronic Bacterial Prostatitis
Yumi Seo and Gilho Lee

Abstract

Purpose
Enterococcus faecalis is one of the most common pathogens linked to chronic bacterial prostatitis (CBP). Owing to a limited number of previous
studies addressing this topic, we aimed to determine the drug resistance patterns of E. faecalis strains isolated from CBP patients.

Materials and Methods

One thousand twenty-one patients visited a single hospital owing to chronic prostatitis for 5 years. Culture specimens were obtained by use of a
modified Meares-Stamey method. The minimal inhibitory concentrations of the antimicrobials were assessed by use of the Vitek II microbial
identification system as suggested by the Clinical and Laboratory Standards Institute.

Results
Forty-one samples from 41 patients who had significant E. faecalis loads for defining CBP were included in this study. The E. faecalis strains in
our study were resistant to penicillin (9.7%), ampicillin (0%), ampicillin/sulbactam (0%), nitrofurantoin (0%), imipenem (0%), vancomycin
(0%), teicoplanin (0%), quinupristin/dalfopristin (100%), ciprofloxacin (9.7%), levofloxacin (4.8%), norfloxacin (26.8%), erythromycin (95%),
gentamicin (46.3%), tetracycline (97.5%), and trimethoprim/sulfamethoxazole (31.5%), respectively.

Conclusions
Fluoroquinolones have been the preferred antibiotics for treating CBP. Because of their low rate of drug resistance, fluoroquinolones are suitable
therapeutic agents for E. faecalis strains causing CBP in Korea. Even though tetracycline, erythromycin, and trimethoprim/sulfamethoxazole
have been prescribed as an empirical antimicrobial therapy for chronic prostatitis, we cannot recommend these drugs for treatment of E. faecalis
isolates because of the high rates of drug resistance.

Keywords: Drug resistance, Enterococcus faecalis, Prostatitis

INTRODUCTION
Chronic bacterial prostatitis (CBP) is diagnosed when a patient has recurrent urinary tract infections (UTIs) caused by bacteria localized in the
prostate. Because it is a relapsing and indolent disease with occasional acute exacerbations, CBP is difficult to treat [1]. The clinical picture of
chronic prostatitis or CBP is one of recurrent episodes of inflammatory voiding symptoms such as frequency, urgency, or dysuria, which are
often associated with suprapubic, genital, perineal, or lower back pain [2,3].

Aerobic gram-negative enteric bacteria have been well documented as the pathogens commonly associated with CBP [1,4]. Even though the role
of gram-positive bacteria in CBP has been controversial, it is well known that Enterococcus faecalis is one of the most prevalent etiologic
pathogens in CBP [5,6].

The approach to treating CBP largely focuses on empirical antibiotic therapy. Various fluoroquinolones have become the standard therapy for
CBP [1,7]. Trimethoprim (TMP) or trimethoprim-sulfamethoxazole (TMP-SMX), tetracycline, and macrolides are also well known as a
traditional second-line treatment of CBP [8,9]. To be effective as therapeutic agents for CBP, the ideal antibiotics must be able to diffuse and
easily penetrate into the prostate tissue. In addition, the ideal antibiotic also shows bacteriocidal susceptibility for each drug [1,9,10].

The current management of chronic prostatitis is usually a long course of empirical antibiotic therapy [10]. Although fluoroquinolones are not
the recommended antibiotic for treatment of enterococcal UTIs, fluoroquinolones are the drug of choice for chronic prostatitis [1,11]. Generally,
these antibiotics are tried without performing a urine or prostate culture or susceptibility testing to guide the therapy. Unfortunately, the
increasing antibiotic resistance today affects the success rate of this empirical treatment. Furthermore, fluoroquinolone resistance by gram-
negative enteric bacteria has been detected at a high rate in the Asia-Pacific region in recent years [12]. Moreover, patients with CBP are usually
treated with inadequate, longer, and repetitive empirical antibiotic therapies because of recurrent episodes of CBP.

The fluoroquinolone-resistant patterns of gram-negative enteric bacteria in UTI have been well studied [12,13]. To our knowledge, however, few
studies have focused on E. faecalis strains isolated from the prostate, even though these organisms are the second most common cause of CBP.
Furthermore, there are few reported data on the antibiotic resistance patterns of E. faecalis from CBP for clinicians to use when choosing an

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3715713/ 1/5
1/11/2020 Antimicrobial Resistance Pattern in Enterococcus faecalis Strains Isolated From Expressed Prostatic Secretions of Patients With Ch…

appropriate empirical therapy. Many urologists believe that the bacterial culture step from prostatic secretion is critical or important for
characterizing infection. However, they usually do not perform the time-consuming prostate culture step.

Nowadays, because the identification of enterococci and the determination of their resistance patterns are important for choosing an empirical
treatment, we aimed to determine the antibiotic resistance patterns of E. faecalis strains isolated from CBP patients in Korea.

MATERIALS AND METHODS

One thousand twenty-one patients visited a single university hospital owing to symptoms suggestive of chronic prostatitis from September 2007
to March 2012. None had taken antimicrobial or anti-inflammatory drugs during the 4 weeks before the evaluation.

According to the National Institutes of Health (NIH) definition, CBP (Category II, NIH-National Institute of Diabetes and Digestive and Kidney
Diseases) is diagnosed when pathogens are cultured from a chronically infected prostate in patients suffering from repeated prostate-specific
symptomatic episodes [14]. The syndrome is characterized by an array of signs and symptoms, including perineal pain, testicular pain and/or
other forms of pelvic pain, irritative and/or obstructive bladder symptoms, ejaculatory pain, and sexual dysfunction [14,15].

Culture specimens for diagnosing CBP were obtained by using a modified Meares-Stamey method [16,17]. In brief, after periurethral cleansing
with an alcohol sponge, the patient provided a VB1 specimen consisting of the initial 5 to 10 mL of voided urine, followed by a VB2 urine
specimen. After production of expressed prostatic secretions (EPS) by digital prostatic massage, the patient provided 5 to 10 mL of voided urine
for the VB3 specimen.

Only one VB1 and one EPS specimen were enrolled per person. Each VB1 specimen was cultured within 4 hours of collection by spreading 100
µL onto plates containing 5% sheep blood and MacConkey's agar, incubated aerobically, and examined for bacterial growth after 48 hours.
Similarly, 100 µL of EPS was cultured onto the same culture plates for 2 days. The criterion for CBP was that the bacterial colony concentration
of the EPS specimens increased by at least 10-fold (one log) compared with the colony numbers of the VB1 specimen.

The minimal inhibitory concentrations (MICs) of the antimicrobials were assessed by use of the Vitek II microbial identification system
(bioMérieux, Marcy-I'Etoile, France) as suggested by the Clinical and Laboratory Standards Institute [12]. The test results were expressed as
MICs with interpretation of the category of microbial susceptibility as susceptible, intermediate, or resistant strains.

Patients were excluded from the analysis if they had active urethral discharge and were also excluded if they had bacteriuria, gross hematuria, or
a urologic diagnosis other than CBP.

RESULTS
Forty-one samples from 1,021 patients (mean age, 61.12±12 years) with significant E. faecalis loads for defining CBP were included in this
study. For easy handling of the data, we placed the E. faecalis isolates with intermediate resistance into the resistant categories of each
antimicrobial.

All 41 stains from 41 patients were sensitive to ampicillin, ampicillin/sulbactam, nitrofurantoin, imipenem, vancomycin, and teicoplanin; 90.3%
were sensitive to penicillin; 68.5% to TMP-SMX; and 53.7% to gentamicin. The quinolone sensitivity of the E. faecalis strains was as follows:
95.2% were sensitive to levofloxacin, 90.3% to ciprofloxacin, and 73.2% to norfloxacin, respectively. Finally, E. faecalis strains in our study
were highly resistant to quinupristin/dalfopristin (100%), erythromycin (95%), and tetracycline (97.5%) (Table 1). The ciprofloxacin
intermediate-resistance strains revealed drug sensitivity to levofloxacin. However, ciprofloxacin-resistant E. faecalis consistently showed drug
resistance to levofloxacin (Table 2). Finally, in Table 3 we summarize the antimicrobial sensitivity of the E. faecalis isolates in this study and in
prostatic penetration studies of the drugs as reviewed in the literature.

TABLE 1
Antimicrobial sensitivity of Enterococcus faecalis isolated from the prostate of patients with chronic bacterial prostatitis

TABLE 2
Fluoroquinolone sensitivity of Enterococcus faecalis isolated from the prostate of patients with chronic bacterial prostatitis

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3715713/ 2/5
1/11/2020 Antimicrobial Resistance Pattern in Enterococcus faecalis Strains Isolated From Expressed Prostatic Secretions of Patients With Ch…

TABLE 3
Drug sensitivity and penetration of drugs into the prostate

DISCUSSION
It is commonly known that only 5% to 10% of chronic prostatitis patients have a bacterial infection detectable by conventional cultures. CBP is a
persistent infection of the prostate characterized by poor quality of life mainly due to frequent relapsing episodes caused by incomplete
eradication of the causative pathogens [18]. Aggressive antibacterial therapy is required to attenuate the severe symptoms of CBP and to achieve
a permanent cure.

Broad consensus exists for the use of fluoroquinolones as first-line antibacterial agents for the treatment of CBP. International guidelines
recommend a 4- to 12-week course of ciprofloxacin, lomefloxacin, ofloxacin, levofloxacin, or norfloxacin for the eradication of susceptible
pathogens [1,7,13].

Norfloxacin and ofloxacin are indicated for the management of CBP caused by E. coli, and ciprofloxacin has been approved for CBP caused by
E. coli or Proteus mirabilis [19]. In addition, levofloxacin is approved for the treatment of CBP caused by E. coli, E. faecalis, or Staphylococcus
epidermidis. However, the norfloxacin sensitivity of the E. faecalis strains from our study was 73.2%. Even though norfloxacin has good
penetration into the prostate, norfloxacin treatment for CBP caused by E. faecalis is not currently justified in Korea [20]. Ciprofloxacin has good
penetration into the prostate and a good prostate tissue-to-plasma ratio [21]. It is well known that ciprofloxacin is currently the most appropriate
antimicrobial agent for the treatment of CBP. Thirty-seven samples revealed ciprofloxacin-sensitive E. faecalis, 2 samples had intermediate
sensitivity to ciprofloxacin, and the last 2 samples showed ciprofloxacin resistance. Levofloxacin sensitivity was shown in 95.2% of the E.
faecalis samples in our study. Furthermore, the samples that showed intermediate resistance to ciprofloxacin had antimicrobial sensitivity to
levofloxacin. However, ciprofloxacin-resistant E. faecalis also consistently showed drug resistance to levofloxacin (Table 2). This finding was
also found in our previous study of antimicrobial resistance patterns in Korean patients with acute uncomplicated cystitis [12]. In addition,
levofloxacin shows a broad antibacterial spectrum for both gram-negative and gram-positive pathogens from CBP. Furthermore, it is dosed on a
once-daily basis and displays significant penetration into the prostate with a favorable prostate tissue-to-plasma ratio [22]. For these reasons, we
conclude that levofloxacin may have better cure rates for E. faecalis from CBP than any other fluoroquinolones such as norfloxacin and
ciprofloxacin.

All E. faecalis strains from our study revealed 100% drug sensitivity to ampicillin and ampicillin/sulbactam and 90.3% drug sensitivity to
penicillin. However, natural penicillin or penicillin derivatives penetrate very poorly into the human prostate [23]. Even though E. faecalis strains
in vitro show high drug susceptibility to these antimicrobials, these drugs have typically shown very low pharmacokinetic levels in prostatic fluid
or tissues.

Nitrofurantoin is widely used for the treatment of UTI. In addition, the E. faecalis strains in our study showed high drug sensitivity to this
antibiotic. Nitrofurantoin is a lipid-soluble weak acid that is somewhat favorable for diffusion into prostatic fluid. However, low levels of
nitrofurantoin were achieved in prostatic fluid in dogs, and the administration of standard oral doses of this drug to men results in lower
therapeutic levels in blood [23,24]. Half of E. faecalis strains showed gentamicin sensitivity in our study. Aminoglycosides do not penetrate
prostatic tissue well, and the prostatic tissue levels of these antibiotics are probably inadequate to eradicate gram-negative bacteria [25].
Furthermore, the oral form of aminoglycosides has not yet been developed. For these reasons, aminoglycosides cannot be recommended as the
ideal therapeutic drug for E. faecalis strains isolated from CBP.

TMP with or without SMX has traditionally been the first-line treatment of CBP. It has been shown that TMP concentrations in the human
prostate are 2 to 3 times higher than those in plasma [26]. TMP with or without SMX can be both theoretically and to some extent
experimentally ideal for gram-negative enterococcal strains from CBP. However, increased drug resistance to TMP-SMX, probably as a result of
the indiscriminate use of this drug in CBP patients, has recently been evidenced [27-29]. Furthermore, TMP may appear active in vitro but is not
effective clinically. We suggest that TMP-SMX may not be an ideal antibiotic for E. faecalis in CBP because the drug sensitivity of the strains in
our study to TMP-SXM was 68.5%.

Tetracycline or tetracycline derivatives have been prescribed as ideal drugs for the treatment of chronic prostatitis. Most tetracyclines have high
lipid solubility, an important factor for ideal antibiotics for the treatment of CBP. However, Quinones et al [30] reported that the tetracycline
resistance rate in E. faecalis was 78.6%, which is similar to our findings. For this reason, tetracycline is not recommended for eradicating the E.
faecalis infection in CBP in Korea.

Imipenem, vancomycin, and teicoplanin have traditionally been reserved as drugs of last resort and are used after treatment with other antibiotics
has failed. However, organisms resistant to these drugs are now common worldwide. In our study, we did not find any drug resistance to
imipenem, vancomycin, or teicoplanin among the E. faecalis strains isolated from patients with CBP. From a pharmacokinetic aspect, imipenem

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3715713/ 3/5
1/11/2020 Antimicrobial Resistance Pattern in Enterococcus faecalis Strains Isolated From Expressed Prostatic Secretions of Patients With Ch…

has been shown to achieve good concentrations in prostatic tissue [23]. There are few data on the use of vancomycin and teicoplanin in chronic
prostatitis.

Quinupristin/dalfopristin is a combination of two antibiotics used to treat infections by staphylococci and by vancomycin-resistant Enterococcus
faecium. However, we cannot recommend this drug for treatment of E. faecalis isolates from CBP patients because of high drug resistance.

We have summarized the antimicrobial sensitivity of the E. faecalis isolates in this study and in prostatic penetration studies of the drugs from
literature reviews in Table 3.

CONCLUSIONS
E. faecalis is one of the most common pathogens in CBP. Fluoroquinolones are strongly recommended as a standard therapeutic agent for CBP
caused by E. faecalis. Even though levofloxacin and ciprofloxacin are suitable therapeutic agents for the treatment of patients with CBP,
levofloxacin may have better cure rates for E. faecalis from CBP than any other fluoroquinolones such as norfloxacin and ciprofloxacin.

Footnotes
The authors have nothing to disclose.

Article information
Korean J Urol. 2013 Jul; 54(7): 477–481.
Published online 2013 Jul 15. doi: 10.4111/kju.2013.54.7.477
PMCID: PMC3715713
PMID: 23878692

Yumi Seo and Gilho Lee

Department of Urology, Dankook University College of Medicine, Cheonan, Korea.

Corresponding author.
Corresponding Author: Gilho Lee. Department of Urology, Dankook University College of Medicine, 119 Dandae-ro, Dongnam-gu, Cheonan 330-997, Korea. TEL: +82-41-
550-3963. FAX: +82-41-551-6630, [email protected]

Received 2013 Feb 18; Accepted 2013 Apr 17.

Copyright © The Korean Urological Association, 2013

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-
nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

This article has been cited by other articles in PMC.

Articles from Korean Journal of Urology are provided here courtesy of Korean Urological Association

References
1. Naber KG, Busch W, Focht J The German Prostatitis Study Group. Ciprofloxacin in the treatment of chronic bacterial prostatitis: a prospective, non-
comparative multicentre clinical trial with long-term follow-up. Int J Antimicrob Agents. 2000;14:143–149. [PubMed] [Google Scholar]

2. Nickel JC, Shoskes DA. Phenotypic approach to the management of the chronic prostatitis/chronic pelvic pain syndrome. BJU Int. 2010;106:1252–
1263. [PubMed] [Google Scholar]

3. Sharp VJ, Takacs EB, Powell CR. Prostatitis: diagnosis and treatment. Am Fam Physician. 2010;82:397–406. [PubMed] [Google Scholar]

4. Meares EM., Jr Bacterial prostatitis vs "prostatosis". A clinical and bacteriological study. JAMA. 1973;224:1372–1375. [PubMed] [Google Scholar]

5. Weidner W, Schiefer HG, Krauss H, Jantos C, Friedrich HJ, Altmannsberger M. Chronic prostatitis: a thorough search for etiologically involved
microorganisms in 1,461 patients. Infection. 1991;19(Suppl 3):S119–S125. [PubMed] [Google Scholar]

6. Cai T, Mazzoli S, Meacci F, Boddi V, Mondaini N, Malossini G, et al. Epidemiological features and resistance pattern in uropathogens isolated from
chronic bacterial prostatitis. J Microbiol. 2011;49:448–454. [PubMed] [Google Scholar]

7. Panagopoulos P, Antoniadou A, Kanellakopoulou K, Tsiodras S, Katsarolis I, Papadopoulos A, et al. Fluoroquinolone treatment of chronic bacterial
prostatitis: a prospective cohort study. J Chemother. 2009;21:317–321. [PubMed] [Google Scholar]

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3715713/ 4/5
1/11/2020 Antimicrobial Resistance Pattern in Enterococcus faecalis Strains Isolated From Expressed Prostatic Secretions of Patients With Ch…

8. Milingos S, Creatsas G, Messinis J, Lolis D, Kaskarelis D. Treatment of chronic prostatitis by consecutive per os administration of doxycycline,
sulfamethoxazole/trimethoprim, and cephalexin. Int J Clin Pharmacol Ther Toxicol. 1983;21:301–305. [PubMed] [Google Scholar]

9. Baumuller A. Antimicrobials for the treatment of bacterial prostatitis. Historical developments and current trends. Scand J Urol Nephrol Suppl.
1987;104:97–99. [PubMed] [Google Scholar]

10. Thakkinstian A, Attia J, Anothaisintawee T, Nickel JC. α-blockers, antibiotics and anti-inflammatories have a role in the management of chronic
prostatitis/chronic pelvic pain syndrome. BJU Int. 2012;110:1014–1022. [PubMed] [Google Scholar]

11. Dalhoff A, Weidner W. Diffusion of ciprofloxacin into prostatic fluid. Eur J Clin Microbiol Infect Dis. 1988;7:438–439. [PubMed] [Google Scholar]

12. Lee G, Cho YH, Shim BS, Lee SD. Risk factors for antimicrobial resistance among the Escherichia coli strains isolated from Korean patients with
acute uncomplicated cystitis: a prospective and nationwide study. J Korean Med Sci. 2010;25:1205–1209. [PMC free article] [PubMed] [Google Scholar]

13. Jang WH, Yoo DH, Park SW. Prevalence of and risk factors for levofloxacin-resistant E. coli isolated from outpatients with urinary tract infection.
Korean J Urol. 2011;52:554–559. [PMC free article] [PubMed] [Google Scholar]

14. Krieger JN, Nyberg L, Jr, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA. 1999;282:236–237. [PubMed]
[Google Scholar]

15. Nickel JC. Prostatitis: evolving management strategies. Urol Clin North Am. 1999;26:737–751. [PubMed] [Google Scholar]

16. Meares EM, Stamey TA. Bacteriologic localization patterns in bacterial prostatitis and urethritis. Invest Urol. 1968;5:492–518. [PubMed]
[Google Scholar]

17. Krieger JN, Ross SO, Limaye AP, Riley DE. Inconsistent localization of gram-positive bacteria to prostate-specific specimens from patients with
chronic prostatitis. Urology. 2005;66:721–725. [PubMed] [Google Scholar]

18. Lee KS, Choi JD. Chronic prostatitis: approaches for best management. Korean J Urol. 2012;53:69–77. [PMC free article] [PubMed] [Google Scholar]

19. Nickel JC, Downey J, Clark J, Ceri H, Olson M. Antibiotic pharmacokinetics in the inflamed prostate. J Urol. 1995;153:527–529. [PubMed]
[Google Scholar]

20. Chen J, Chen RR, Huang HS. Comparison of ofloxacin and norfloxacin concentration in prostatic tissues in patients undergoing transurethral resection
of the prostate. J Formos Med Assoc. 2001;100:548–552. [PubMed] [Google Scholar]

21. Grabe M, Forsgren A, Bjork T. Concentrations of ciprofloxacin in serum and prostatic tissue in patients undergoing transurethral resection. Eur J Clin
Microbiol. 1986;5:211–212. [PubMed] [Google Scholar]

22. Drusano GL, Preston SL, Van Guilder M, North D, Gombert M, Oefelein M, et al. A population pharmacokinetic analysis of the penetration of the
prostate by levofloxacin. Antimicrob Agents Chemother. 2000;44:2046–2051. [PMC free article] [PubMed] [Google Scholar]

23. Charalabopoulos K, Karachalios G, Baltogiannis D, Charalabopoulos A, Giannakopoulos X, Sofikitis N. Penetration of antimicrobial agents into the
prostate. Chemotherapy. 2003;49:269–279. [PubMed] [Google Scholar]

24. Dunn BL, Stamey TA. Antibacterial concentrations in prostatic fluid. 1. Nitrofurantoin. J Urol. 1967;97:505–507. [PubMed] [Google Scholar]

25. Dyderski S, Sokołowski W. Gentamicin level in the prostate and its pharmacokinetics in patients with benign prostatic hypertrophy. Pol Tyg Lek.
1990;45:517–519. [PubMed] [Google Scholar]

26. Oosterlinck W, Defoort R, Renders G. The concentration of sulphamethoxazole and trimethoprim in human prostate gland. Br J Urol. 1975;47:301–
304. [PubMed] [Google Scholar]

27. Schaeffer AJ, Darras FS. The efficacy of norfloxacin in the treatment of chronic bacterial prostatitis refractory to trimethoprim-sulfamethoxazole
and/or carbenicillin. J Urol. 1990;144:690–693. [PubMed] [Google Scholar]

28. Fowler JE., Jr Antimicrobial therapy for bacterial and nonbacterial prostatitis. Urology. 2002;60(6 Suppl):24–26. [PubMed] [Google Scholar]

29. Sharer WC, Fair WR. The pharmacokinetics of antibiotic diffusion in chronic bacterial prostatitis. Prostate. 1982;3:139–148. [PubMed]
[Google Scholar]

30. Quinones D, Goni P, Rubio MC, Duran E, Gomez-Lus R. Enterococci spp. isolated from Cuba: species frequency of occurrence and antimicrobial
susceptibility profile. Diagn Microbiol Infect Dis. 2005;51:63–67. [PubMed] [Google Scholar]

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3715713/ 5/5